Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations - Assets and liabilities reported as discontinued operations in balance sheet (Details)

v3.21.2
Discontinued Operations - Assets and liabilities reported as discontinued operations in balance sheet (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2021
Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Discontinued operations - current assets     $ 187 $ 181
Discontinued operations - current liabilities     1,113 1,960
U.S. commercialization activities | Discontinued operations        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Receivables     160 0
Prepaid expenses and other current assets     27 181
Discontinued operations - current assets     187 181
Accounts payable     752 1,515
Accrued clinical trials expenses     9 80
Accrued sales allowances       61
Other accrued liabilities     352 304
Discontinued operations - current liabilities     $ 1,113 $ 1,960
Non-cash stock-based compensation expenses $ 9,000 $ 110,000